Selumetinib Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The global selumetinib market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Selumetinib, marketed under the brand name Koselugo, is a drug for children, two years of age and older, with type neurofibromatosis I (NF-1), a genetic disorder of the old nervous system that develops nerve implants. The market is driven by growing awareness of neurofibromatosis disease and the need for drug infection control procedures in all health care settings. Increasing focus of major players in the R&D of novel therapies for the treatment of neurofibromatosis is further anticipated to drive the market growth. In addition, clinical studies are well supported by regulatory authorities that are expected to advance the growth of the global selumetinib market.

For instance, in October 2019, SpringWorks Therapeutics, Inc., a clinical category biopharmaceutical company focused on developing life-changing medications for patients with very rare diseases and cancers, launched a Phase 2b ReNeu clinical trial to test trametinib (formerly PD- 0325901), an oral, small molecule designed to block MEK1 and MEK2, in children and adult patients with neurofibromatosis type 1 (NF1) -associated plexiform neurofibromas (NF1-PN).

The key market players such as GlaxoSmithKline plc, Sanofi SA, Pfizer Inc., and Cipla Inc. are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product development. For instance, on February 18, 2020, the University of Alabama at Birmingham began clinical trials of phase 2 crizotinib in children and adults with type 2neurofibromatosis and progressive vestibular, which created the demand of the selumetinib market growth.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Disease Type
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape-GlaxoSmithKline plc, Sanofi SA, Pfizer Inc., and Cipla Inc. among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Selumetinib MarketReport by Segment

By Disease Type

• Neurofibromatosis 1 (NF1)
• Neurofibromatosis 2 (NF2),

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies